4D Molecular Therapeutics’ $120 Million Common Stock Offering

Latham & Watkins advised 4D Molecular Therapeutics, while Cooley advised the underwriters for the offering.4D Molecular Therapeutics, Inc. has announced that it priced an upsized underwritten…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Pietro Martinoia

This content is for Standard 1 Year members only.
Login Join Now